Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up24/7 Wall Street • 3h
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?Zacks Investment Research • Thursday
Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to KnowZacks Investment Research • Thursday
Moderna's CEO told The Wall Street Journal that his cancer vaccine's data will get better with time, and that no one can easily copy the company's workWSJ • Wednesday
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher24/7 Wall Street • Wednesday
Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp VolatilityThe Motley Fool • Wednesday
William Blair Takes a Shot at Moderna Stock: Downgrade to Market Perform After a 545% RunBenzinga • Tuesday
Moderna Recovers From 10% Dive, But Muted Expectations Haunt Cancer VaccineInvestors Business Daily • Monday
Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady24/7 Wall Street • Monday
Moderna, Inc. (MRNA) Discusses Phase III Data for Intismeran and Advances in Cancer Immunotherapy TranscriptSeeking Alpha • 10/24/26
Heard on the Street: Moderna's cancer vaccine passed its first big test this past week. The bigger problem is that its stock is priced as if it has already passed them all.WSJ • 10/24/26
To the scientific world, Moderna's cancer vaccine's results proved that a highly personalized, immune-targeting medication can work. To investors, it didn't work well enough.WSJ • 10/23/26
The real test for Moderna's cancer vaccine isn't about beating Keytruda. It's keeping cancer from coming back in the long term.Market Watch • 10/23/26
MRNA Tanks as Positive Phase III Cancer Therapy Data Fails to ImpressZacks Investment Research • 10/23/26
Merck And Moderna Diverge On Cancer Vaccine Results. Do They Still Have A Viable Drug?Investors Business Daily • 10/23/26